Lincoln Pharma Q2 FY27: PAT up 2% YoY as margins compress, revenue +17%
PAT +2.21% YoY · revenue +17.13% · margins compressing
₹191.35 Cr
+17.13% YoY
₹20.43 Cr
+2.21% YoY
10.17%
-1.5pp YoY
₹10.2
Lincoln Pharmaceuticals reported consolidated (and effectively identical standalone) revenue from operations of ₹191.35 Cr for Q2 FY27, up 17.1% YoY from ₹163.36 Cr and up 7.9% QoQ from ₹177.28 Cr in Q1 FY27. Profit did not keep pace: consolidated PAT was ₹20.43 Cr, up just 2.2% YoY from ₹19.98 Cr, and down 43.6% QoQ from ₹36.23 Cr in Q1 FY27. EPS was ₹10.20 against ₹9.98 a year earlier. Neither period carried exceptional items, so this is a clean like-for-like reported comparison, not a one-off distortion.
Q2 FY-2027 vs prior quarters
The gap between revenue and profit growth shows up in margins. Operating margin (PBT + finance cost + depreciation, less other income, over revenue from operations) fell to roughly 12.4% from about 15.5% both a year ago and last quarter, while net profit margin on total income slipped to 10.2% from 17.98% in Q1 FY27 and 11.71% in Q2 FY26. Total expenses rose faster than income this quarter, with cost of materials consumed the single largest line at ₹77.47 Cr. Tax of ₹8.59 Cr included a ₹1.74 Cr short provision for prior years, a modest additional drag on reported PAT but not the main story — the main story is expense growth outrunning revenue growth.
The stock went into the print at ₹511.9, down 12% over the past month of trading.
No street estimates could be found for this print: a pre-result preview explicitly noted that no analyst consensus for Lincoln Pharma's Q2 FY27 was in the public domain, so vsStreet is unknown rather than inferred. The company also has no formal prior guidance on record for this specific quarter, so the print cannot be graded against a stated target; alongside results it reiterated a three-year ambition of ₹1,000 Cr revenue at 15-18% annual growth led by cardiac, diabetic, dermatology and ENT segments — a forward target, not a backward-looking guidance score. During the quarter the company launched four new domestic divisions and commissioned an API facility at its Khatraj plant, closed its trading window ahead of results, saw its senior QA General Manager resign (with a replacement appointed the same week), held its 32nd AGM approving an FY26 final dividend of ₹1.80/share, and saw FII holding rise to 4.55% as of September 30, 2026 — none of which directly explains the margin compression, which traces to the expense-side numbers above.
W1
Whether operating margin recovers toward the ~15.5% run-rate seen in Q1 FY27 and Q2 FY26, or Q2 FY27's ~12.4% is the new baseline.
W2
Progress on the ₹1,000 Cr/15-18% annual growth target management reiterated this quarter — track H2 FY27 revenue against H1 FY27's ₹402.43 Cr.
W3
Whether the four new domestic divisions and the Khatraj API facility commissioned this quarter begin contributing to revenue and margin in H2 FY27.
Consolidated and standalone are numerically identical this quarter — subsidiary Zullinc Healthcare LLP (total assets ₹140.53 Lakh) contributed nil income/profit per the auditor's review note; no exceptional items in either period.
Informational and educational content only. Not investment advice.